AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Aligos Therapeutics Inc. (ALGS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

24.20

-0.56 (-2.26%)

At close: Jan 29, 2025, 3:59 PM

24.10

-0.43%

After-hours Jan 29, 2025, 05:04 PM EST

undefined% (undefined)

Bid	24.1
Market Cap	83.85M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-7.25
PE Ratio (ttm)	-3.34
Forward PE	n/a
Analyst	Buy

Ask	24.99
Volume	154,989
Avg. Volume (20D)	473,850
Open	24.83
Previous Close	24.76
Day's Range	24.03 - 26.40
52-Week Range	6.76 - 46.80
Beta	undefined

About ALGS

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The com...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 16, 2020

Employees 68

Stock Exchange NASDAQ

Ticker Symbol ALGS

Website https://www.aligos.com

Analyst Forecast

According to 1 analyst ratings, the average rating for ALGS stock is "Buy." The 12-month stock price forecast is $75, which is an increase of 209.85% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Aligos Therapeutics Inc. is scheduled to release its earnings on Mar 11, 2025, during market hours.
Analysts project revenue of $433.33K, reflecting a -78.43% YoY shrinking and earnings per share of -3.67, making a -33.27% decrease YoY.

Why Price Moved

2 months ago

+6.1%

Aligos Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

4 months ago

-28.11%

Aligos Therapeutics shares are trading lower. The company announced results from its Phase 2a HERALD study.

News

2 months ago · zacks.com

Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.07 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to loss of $10.25 per share a year ago.

3 months ago · businesswire.com

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting .